Related Experiment Video
Updated: Jun 28, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
New biologic agents and immunologic strategies
Rebecca L Elstrom1, Peter Martin, John P Leonard
1Division of Hematology/Oncology, Weill Cornell Medical College, 520 East 70th Street, Starr 340, New York, NY 10021, USA.
Abstract:
The treatment of non-Hodgkin lymphoma has traditionally consisted of cytotoxic chemotherapy, which can frequently induce remissions but less reliably delivers long-term disease-free survival. The last two decades have heralded an era of increasing exploration of therapies derived from improved biologic understanding of tumors and tumor-host interactions, including the development of therapeutic tactics that take advantage of immune mechanisms to target and kill tumors. Foremost among these has been the development of monoclonal antibodies. Currently, an array of novel therapeutics in development may improve outcomes further, including novel monoclonals and other agents that take advantage of or optimize immune system function in the treatment of lymphoma or that provide other mechanisms of antitumor activity.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Microorganisms in Medicine and Therapeutics
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
